美国食品和药物管理局拒绝批准百健公司更高剂量的遗传性疾病药物

路透中文
Sep 24, 2025
<a href="https://laohu8.com/S/USFD">美国食品</a>和药物管理局拒绝批准百健公司更高剂量的遗传性疾病药物

路透社9月23日 - 美国食品和药物管理局拒绝批准百健公司BIIB.O治疗一种导致进行性肌无力的罕见遗传性疾病的高剂量药物,这使该公司在激烈的市场竞争中巩固地位的努力遭遇挫折。

(为便利非英文母语者,路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误,或未能包含所需语境,路透不保证自动化翻译文本的准确性,仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失,路透不承担任何责任。)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10